Biosimilar medicines and cost-effectiveness

Biosimilar medicines and cost-effectiveness

Steven SimoensResearch Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Given that biosimilars are agents that are similar but not identical to the reference biopharmaceutical, this study aims to intro...

Full description

Bibliographic Details
Main Author:	Steven Simoens
Format:	Article
Language:	English
Published:	Dove Medical Press 2011-02-01
Series:	ClinicoEconomics and Outcomes Research
Online Access:	http://www.dovepress.com/biosimilar-medicines-and-cost-effectiveness-a6291

Similar Items

Generic and biosimilar medicines: quid?
by: Steven Simoens
Published: (2012-12-01)

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
by: Yannick Vandenplas, et al.
Published: (2021-02-01)

Tendering and biosimilars: what role for value-added services?
by: Steven Simoens, et al.
Published: (2020-01-01)

Emerging Insights into European Markets of Biologics, Including Biosimilars
by: Steven Simoens, et al.
Published: (2022-05-01)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
by: Yannick Vandenplas, et al.
Published: (2022-01-01)

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
by: Yannick Vandenplas, et al.
Published: (2021-04-01)

From generic to biosimilar drugs: why take an innovative pace?
by: Fereshteh Barei, et al.
Published: (2012-12-01)

The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis
by: Yannick Vandenplas, et al.
Published: (2023-07-01)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
by: Steven Simoens, et al.
Published: (2021-05-01)

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
by: Evelien Moorkens, et al.
Published: (2020-01-01)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
by: Liese Barbier, et al.
Published: (2022-07-01)

R&D Costs of New Medicines: A Landscape Analysis
by: Steven Simoens, et al.
Published: (2021-10-01)

A Regulatory Perspective on Biosimilar Medicines
by: Marta Agostinho Cordeiro, et al.
Published: (2024-02-01)

Comparative Studies of Biosimilar Medicinal Products
by: O. B. Talibov
Published: (2019-06-01)

Biosimilar medicines uptake: The role of the clinical pharmacist
by: Roland Nnaemeka Okoro
Published: (2021-03-01)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
by: Coates, L, et al.
Published: (2022)

Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
by: Liese Barbier, et al.
Published: (2021-12-01)

Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices
by: Liese Barbier, et al.
Published: (2021-05-01)

An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain
by: Teresa Barcina Lacosta, et al.
Published: (2023-01-01)

Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters
by: HoUng Kim, et al.
Published: (2021-01-01)

The cost-effectiveness of prevention: is an ounce of prevention worth a pound of cure?
by: Steven Simoens
Published: (2012-03-01)

Biosimilar medicines and patient registries – expectations, limitations, and opportunities
by: Sutka R, et al.
Published: (2017-12-01)

Economic Advantages of Domestic Production of Biosimilar Medicines in Iran
by: Nazila Yousefi, et al.
Published: (2023-09-01)

How to assess the value of medicines?
by: Steven Simoens
Published: (2010-09-01)

Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution?
by: Chatzimichail E, et al.
Published: (2024-02-01)

Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies
by: Steven Simoens
Published: (2022-10-01)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
by: Evelien Moorkens, et al.
Published: (2020-10-01)

Potential Cost-Savings From the Use of the Biosimilars in Slovakia
by: Tomas Tesar, et al.
Published: (2020-08-01)

Biosimilars
by: Emel Bülbül Başkan
Published: (2022-04-01)

Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging
by: Liese Barbier, et al.
Published: (2022-03-01)

Biological medicinal products: reference and biosimilar products – selected issues
by: Bartosz Kobuszewski
Published: (2021-10-01)

Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
by: Teresa Barcina Lacosta, et al.
Published: (2022-12-01)

Revising the Guidance Document for Biosimilar Agents
by: Steven Williams
Published: (2017-04-01)

Revising the Guidance Document for Biosimilar Agents
by: Steven Williams
Published: (2017-04-01)

Estudos de medicamentos biosimilares Studies on biosimilar medications
by: Winston Bonetti Yoshida
Published: (2010-09-01)

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends
by: Elif Car, et al.
Published: (2023-04-01)

Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review
by: Arnold G. Vulto, et al.
Published: (2020-11-01)

Prescribing biosimilars
by: Aronson, J, et al.
Published: (2018)

BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
by: Alina Uifălean, et al.
Published: (2018-09-01)